The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain
2008

How Vif Protein Helps HIV-1 Overcome Drug Inhibition

publication Evidence: moderate

Author Information

Author(s): DaFonseca Sandrina, Coric Pascale, Gay Bernard, Hong Saw See, Bouaziz Serge, Boulanger Pierre

Primary Institution: Université de Lyon I – Claude Bernard

Hypothesis

Can viral proteins modulate the susceptibility of HIV-1 to the drug DSB?

Conclusion

The Vif protein of HIV-1 can counteract the inhibitory effects of DSB on virus-like particle assembly, depending on its zinc-binding domain.

Supporting Evidence

  • Vif protein restored VLP production in DSB-treated cells to control levels.
  • Vif mutants lacking the zinc-binding domain could not counteract DSB's effects.
  • Electron microscopy showed VLP were redirected to vesicular compartments in the presence of Vif.

Takeaway

A protein called Vif helps HIV-1 fight against a drug that tries to stop it from making new virus particles. If Vif is damaged, the drug works better.

Methodology

The study involved coexpressing viral proteins with HIV-1 Gag in insect cells and assessing the effects of DSB on virus-like particle assembly.

Limitations

The study was conducted in insect cells, which may not fully replicate human cellular responses.

Digital Object Identifier (DOI)

10.1186/1743-422X-5-162

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication